Ion Beam Applications S.A. announced the start of the installation of a Cyclone 30 XP in Poland. There are now three sites set to produce Astatine-211 (At-211) for oncology applications, reaffirming IBA's leadership and innovation in the area of radiotheranostics. The completion of the rigging in POLATOM on December 11th follows the successful commissioning of the first Cyclone 30 XP machine in Julich, Germany, earlier this year.

Furthermore, an IBA cyclotron Cyclone 70 XP, installed in France in 2008, has enabled multiple research programs already. IBA and the three sites, ARRONAX (France), Forschungszentrum Julich (Germany), and POLATOM (Poland), are active participants in COST Action 19114: A European Network Dedicated to Targeted Alpha Therapy (TAT) with At-211. This collaborative effort showcases a commitment to overcoming challenges and advancing targeted alpha therapy research.

Despite its scarcity, At-211, an alpha emitter, is used in clinical research for targeted alpha-therapies in the field of oncology to treat brain, thyroid, ovarian, breast, prostate cancer1. Beyond At-211, IBA is also pioneering novel accelerator applications for other theranostic isotopes.